Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

tients for the FDG-PET clinical trial, as well as any future clinical trial; -- failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials; -- our ability to successfully complete our clinical trials of VIA- 2291 on expected timetables and the outcomes of such clinical trials; -- complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays; -- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and CEA studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- our ability to obtain necessary FDA approvals; -- our ability to successfully commercialize VIA-2291; -- our ability to obtain and protect our intellectual property related to our product candidates; -- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche; -- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates; -- general economic and business conditions; and -- the other risks described under Item IA "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008 on file with the SEC.

All forward
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 , ... Evaluate the Ability of,Cardiopoietic Cells to Restore Cardiac ... a leading Belgian biotechnology company specialising,in cell-based therapies ... it has completed, two months ahead of schedule,enrolment ... II/III trial of C-Cure, a,unique stem cell therapy ...
(Date:12/14/2009)... BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 ... ) and Amgen Inc.(Nasdaq: AMGN ) today ... Amgen exclusive worldwide rights to Array,s small-molecule glucokinase ... a Phase 1 clinical trial in patients with ... terms of the agreement, Array will receive an ...
(Date:12/14/2009)... International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today ... Scripps Research Institute ("Scripps") by entering into an ... Dyadic,s patented and proprietary C1 fungus ("C1"). ,, ... relationship between the two organizations which began in ... the C1 genome for the first time. The ...
(Date:12/14/2009)... The third edition of Infusion Nursing: ... by the Infusion Nurses Society (INS), includes Totect(®), ... Anthracyclines are a group of chemotherapy medications including ... used in the treatment of various types of ... According to the INS publication: "In September 2007, ...
Breaking Biology Technology:Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... for solid tumors and,hematological malignancies, invites all interested parties ... Annual Analyst Day beginning at 9:30 a.m. ET,(6:30 a.m. ... on Tuesday,April 29, 2008., Investors and interested parties ...
... Renovis, Inc.,(Nasdaq: RNVS ), today announced that Glass ... ISS/Risk Metrics in recommending that Renovis,stockholders vote "FOR" the ... the Special Stockholders Meeting scheduled for May,1, 2008. In ... will be,converted into the right to receive the equivalent ...
... of Bioterrorism, Says UK Board ... Member General Lord Guthrie, BOSTON, April ... and deploy technology that can neutralize and destroy,a biohazardous substance while ... with General Lord Guthrie,former chief of the British Defense Staff, to ...
Other Biology Technology:Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 2Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 3Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 2Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 3
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/13/2009)... resolved a question about how a popular class ... biosensors that reveal previously hidden components of chemical ... and hallucinations characterize the illness, people with schizophrenia ... in a particular order, difficulties that interfere with ... well, said Lee Schroeder, a student in the ...
(Date:12/11/2009)... increases, growers are being challenged to bring consistently ... bottom line, orchard owners are experimenting with new ... labor costs. , Hand thinning, a common practice ... is among the most labor-intensive of orchard practices, ... and, ultimately, prices paid by consumers. A research ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Horizontal string trimmer reduces labor costs, increases peach size 2Pragmedic Implements World Class Healthcare Solution for Emaar Healthcare 14646 1Pragmedic Implements World Class Healthcare Solution for Emaar Healthcare 14646 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 1Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 2Rogan Delft Approves Matrox Xenia Series for Use With Zillion Suite 5831 3Practice changing cancer studies presented at major cancer meeting 60320 1Practice changing cancer studies presented at major cancer meeting 60320 2
... test for the two strains of human papillomavirus responsible for ... assay uses a cervical scraping, like that for a liquid-based ... responsible for 70 percent of cervical cancers, says Dr. Daron ... Cancer Prevention Center at the Medical College of Georgia. ...
... make cholesterol, a team of scientists has discovered ... production and potentially drug metabolism. , The collaborative ... of Medicine, Vanderbilt University, Indiana University and Eli ... of Cell Metabolism. , “Dap1 controls ...
... agriculture now will we meet the acute water-environment-poverty challenges facing ... land and human resources it is possible to produce enough ... food production and environmental trends will lead to crises in ... General of the International Water Management Institute. , This is ...
Other Biology News:New test for most virulent HPV strains under study 2New test for most virulent HPV strains under study 3Primitive yeast yields secrets of human cholesterol and drug metabolism 2Living with water scarcity -- world must act now 2Living with water scarcity -- world must act now 3Living with water scarcity -- world must act now 4Living with water scarcity -- world must act now 5
... up to 6 strain chambers with precise uniaxial ... design ensures that cells grow over long periods ... This unit allows you to control the frequency ... unique strain settings. The instrument fits in a ...
... The Guava PCA-96 systems provide automated, ... a tray of microcentrifuge tubes. This flexible ... ideal for screening in basic research, target ... Like it's smaller cousin, the Guava PCA-96 ...
... 250 g monoclonal antibody irreversibly crosslinked ... ~13 g of PDH complex from heart ... bovine heart mitochondria for control immunocapture. ,The ... isolation of PDH from small amounts of ...
... cells permits studies of protein-protein interactions, protein ... transcription factor-mediated gene regulation. The most rapid ... specific protein in a mammalian cell is ... cell. ProteoJuice Protein Transfection Reagent is an ...
Biology Products: